Not provided
| ID | Type | Description | Link |
|---|---|---|---|
| NCI-2022-05693 | Registry Identifier | CTRP (Clinical Trial Reporting Program) | |
| STUDY00009998 | Other Identifier | Fred Hutch/University of Washington Cancer Consortium |
Not provided
Not provided
Not provided
Study closed due to no accruals and change in the standard of care for this population
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
| Name | Class |
|---|---|
| Guerbet | INDUSTRY |
Not provided
Not provided
Not provided
Not provided
This phase I trial tests whether embolization done prior to surgery (preoperative) will improve surgical outcomes in head and neck tumors with large amounts of blood vessels (hypervascular). Embolization is a minimally invasive surgical technique performed under angiographic (imaging of blood vessels) guidance. Embolization therapy injects tiny particles into the arteries feeding tumors to cut off their blood supply which may help improve outcomes by preventing blood loss during surgery, reducing surgical times, and shrinking tumors or reducing recurrence.
OUTLINE:
Patients receive iodixanol via injection and undergo diagnostic cerebral angiogram over 30 minutes. If the tumor blood supply is suitable, patients undergo tumor vessel embolization with polyvinyl alcohol (PVA) suspended in ethiodized oil (EOV) and delivered via a catheter. Patients also undergo head and neck computed tomography (CT) scans immediately after completion of tumor vessel embolization, and again between 2-3 months later.
After completion of study, patients are followed for up to 6 months.
Not provided
Not provided
Not provided
Not provided
Not provided
| Label | Type | Description | Intervention Names |
|---|---|---|---|
| Treatment (PVA, EOV, tumor vessel embolization) | Experimental | Patients receive iodixanol via injection and undergo diagnostic cerebral angiogram over 30 minutes. If the tumor blood supply is suitable, patients undergo tumor vessel embolization with PVA suspended in EOV and delivered via a catheter. Patients also undergo head and neck CT scans immediately after completion of tumor vessel embolization, and again between 2-3 months later. |
|
| Name | Type | Description | Arm Group Labels | Other Names |
|---|---|---|---|---|
| Iodixanol | Other | Given via injection |
|
| Measure | Description | Time Frame |
|---|---|---|
| Intraoperative blood loss | Defined as the volume of blood lost (mL) from skin incision to skin closure. | Intraoperatively |
| Measure | Description | Time Frame |
|---|---|---|
| Perioperative blood transfusion volume | Defined as the volume (mL) of packed red blood cells infused. | Intraoperatively and until 48 hours postoperatively |
| Surgical procedure time | Defined as the amount of time (minutes) from skin incision to skin closure. |
Not provided
Inclusion Criteria:
Exclusion Criteria:
Not provided
Not provided
Not provided
Not provided
Not provided
| Name | Affiliation | Role |
|---|---|---|
| Melanie Walker | Fred Hutch/University of Washington Cancer Consortium | Principal Investigator |
| Do Lim | Fred Hutch/University of Washington Cancer Consortium | Study Director |
| Facility | Status | City | State | ZIP | Country | Contacts |
|---|---|---|---|---|---|---|
| Fred Hutch/University of Washington Cancer Consortium | Seattle | Washington | 98109 | United States |
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
| Angiogram | Procedure | Undergo diagnostic cerebral angiogram |
|
| Arterial Embolization | Procedure | Undergo tumor vessel embolization |
|
|
| Polyvinyl Alcohol | Drug | Given via catheter |
|
|
| Ethiodized Oil | Drug | Given via catheter |
|
|
| Computed Tomography | Procedure | Undergo head and neck CT scans |
|
|
| Chart Abstraction | Other | Ancillary studies |
|
| Time (minutes) from skin incision to skin closure |
| Success of embolization | Defined as percent reduction in vascular blush from tumor supply vessels on catheter angiogram. | Directly after the embolization |
| Adverse events (AE) related to angiography or embolization | Defined as neurological deficit(s) on clinical examination. | Directly after embolization and for 24 hours post-embolization |
| ID | Term |
|---|---|
| C044834 | iodixanol |
| D011142 | Polyvinyl Alcohol |
| D004998 | Ethiodized Oil |
| D007459 | Iodized Oil |
| ID | Term |
|---|---|
| D000438 | Alcohols |
| D009930 | Organic Chemicals |
| D011145 | Polyvinyls |
| D014753 | Vinyl Compounds |
| D000475 | Alkenes |
| D006839 | Hydrocarbons, Acyclic |
| D006838 | Hydrocarbons |
| D010969 | Plastics |
| D011108 | Polymers |
| D046911 | Macromolecular Substances |
| D001697 | Biomedical and Dental Materials |
| D008420 | Manufactured Materials |
| D013676 | Technology, Industry, and Agriculture |
| D010938 | Plant Oils |
| D009821 | Oils |
| D008055 | Lipids |
| D028321 | Plant Preparations |
| D001688 | Biological Products |
| D045424 | Complex Mixtures |
Not provided
Not provided